medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
   Distinct serum anti-AÎ² antibody patterns in hemorrhagic and inflammatory
                                 cerebral amyloid angiopathy manifestations
 Yannick Chantran, PharmD1,2, Jean Capron, MD1,3, Diana Doukhi, MD1, Johanna Felix1, MÃ©lanie
 FÃ©roul1, Florian Kruse1, Thomas Chaigneau1, Guillaume DorothÃ©e, PhD1, Thibault Allou, MD4,
 Xavier Ayrignac, MD,5 Zina Barrou, MD,6 Thomas de Broucker, MD,7 Corina Cret,MD,8 Guillaume
 Turc, MD, PhD,9 Roxane Peres, MD,10 Anne Wacongne, MD,11 Marie Sarazin, MD PhD,12 Dimitri
 Renard, MD,11 Charlotte Cordonnier, MD PhD,13 Sonia Alamowitch, MD PhD1,3, Pierre Aucouturier,
 MD PhD1,2*
 1
   UMRS 938, HÃ´pital St-Antoine, Sorbonne UniversitÃ©, Inserm, Paris, France
 2
   DÃ©partement dâ€™Immunologie Biologique, HÃ´pital Saint-Antoine, AP-HP, Paris, France
 3
   Service de Neurologie et dâ€™Urgences Neurovasculaires, HÃ´pital Saint-Antoine, AP-HP, Paris, France
 4
   Service de Neurologie, CH Perpignan, Perpignan, France
 5
   Service de Neurologie, CHU Montpellier, HÃ´pital Guy de Chauliac, Montpellier, France
 6
   Service de GÃ©riatrie, HÃ´pital PitiÃ© SalpÃªtriÃ¨re, AP-HP, Paris, France
 7
   Service de Neurologie, Centre Hospitalier de Saint-Denis, Saint-Denis, France
 8
   Service de Neurologie, Centre Hospitalier de Meaux, Meaux, France
 9
   Service de Neurologie, GHU Paris Psychiatrie et Neurosciences, UniversitÃ© de Paris, INSERM U1266, FHU
 NeuroVasc, Paris, France
 10
    Service de Neurologie, HÃ´pital LariboisiÃ¨re, AP-HP, Paris, France
 11
    Service de Neurologie, CHU NÃ®mes, HÃ´pital Caremeau, NÃ®mes, France
 12
    Service de Neurologie de la MÃ©moire et du Langage, Centre Hospitalier Sainte-Anne, UniversitÃ© Sorbonne
 Paris CitÃ©, Paris, France
 13
    U1172 - LilNCog - Lille Neuroscience & Cognition, Inserm, CHU Lille, Univ. Lille, Lille, France
      NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 * Correspondence:
 Pierre Aucouturier
 pierre.aucouturier@inserm.fr
 Keywords: anti-AÎ² antibodies, natural antibodies, cerebral amyloid angiopathy, stroke, AÎ² related
 angiitis.
 Study funding : supported by the SATT Lutech
                                                                                                                                           2

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Abstract
 Objective: To study blood anti-AÎ² antibodies in the context of spontaneous inflammatory or
 hemorrhagic CAA manifestations, which are similar to complications occurring after monoclonal
 anti-AÎ² antibody immunotherapies.
 Methods: In this case-control study, serum anti-AÎ² antibody isotype, concentration, avidity, and
 reactivity toward soluble or fibrillary AÎ²1-40 and AÎ²1-42 isoforms were assessed using an ELISA-
 based multiplex analysis. Anti-AÎ² serologic patterns were defined in CAA and CAA subgroups using
 multivariable logistic regression analyses.
 Results: Fourty-one healthy aged controls and 64 CAA patients were recruited: 46 with hemorrhagic
 features (CAA-he) and 18 with CAA-related inflammation (CAA-ri). As compared to controls, the
 most striking features of CAA-related serological profiles were the following: i) both CAA-he and
 CAA-ri patients displayed lower binding diversity of anti-soluble AÎ²1-40 IgM; ii) CAA-he patients
 displayed higher anti-soluble AÎ²1-40 / fibrillary AÎ²1-42 IgG4 concentrations ratio and higher anti-
 soluble AÎ²1-42 IgG4 and IgA avidity; iii) CAA-ri patients displayed higher binding diversity of anti-
 soluble AÎ²1-40 IgG3 and higher anti-fibrillary/soluble AÎ²1-42 IgG4 dilution curve steepness ratio.
 Conclusion: This proof-of-concept study revealed anti-AÎ² antibody variations in CAA patients, some
 of which were associated to CAA clinical phenotypes, unveiling pathophysiological insights
 regarding CAA-hemorrhagic and inflammatory related events.
                                                                                                                                           3

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Introduction
 Cerebral amyloid angiopathy (CAA) relates to cortical and leptomeningeal vessel microangiopathy
 with accumulation of vascular amyloid fibrils made of amyloid-Î² peptide (AÎ²).1 CAA is frequent in
 both Alzheimerâ€™s disease (AD) and non-AD aged participants. Intracerebral hemorrhage (ICH)
 related to CAA (CAA-he) is a major health concern.2 CAA-related inflammation (CAA-ri) is a rare
 but treatable AÎ²-related CNS vasculitis.3
 Dose-dependent adverse events similar to CAA-he and CAA-ri were observed upon anti-AÎ²
 immunotherapy in AD,4 suggesting a role of anti-AÎ² antibodies in CAA manifestations. Subsequent
 investigations revealed elevated CSF levels of anti-AÎ² IgG during CAA-ri.5,6 However, it was shown
 experimentally that blood-borne more than CSF-borne anti-AÎ² antibodies can aggravate CAA
 manifestations in mouse models.7,8
 As well as other auto-antibodies involved in neurodegenerative disorders, including anti-Tau protein9
 and anti-alpha synuclein antibodies,10 anti-AÎ² antibodies belonging to the â€œnaturalâ€ auto-antibody
 repertoire: they are present in both diseased and healthy individuals, displaying low-avidity and
 multi-reactivity, and circulating mostly as immune complexes.11 These complexes require
 dissociation prior to analysis, in order to reveal serological specificities in AD.11,12 These features
 have likely hindered consistent analyses regarding anti-AÎ² antibodies, which was also the case for
 anti-alpha synuclein antibodies.10 In AD, anti-AÎ² antibodies measurement led to inconsistent
 conclusions.11-14 Circulating anti-AÎ² antibodies were scarcely studied in CAA.
 Our working hypothesis was that CAA and related clinical manifestations would relate to particular
 characteristics of serum anti-AÎ² antibodies, including concentration, avidity, specific reactivity
 towards AÎ² isoforms, and class and subclass diversity.
                                                                                                                                           4

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Materials and methods
 Study design and participants
 This case-control study enrolled participants from Jan. 2013 to Jun. 2019, through nine French
 medical centers: CAA patients, and healthy aged controls lacking clinical and MRI features of CAA.
 Patients with CAA were classified into: CAA-he inpatients with probable or definite CAA according
 to the modified Boston criteria;15,16 CAA-ri inpatients fulfilling the criteria for non-invasive diagnosis
 of CAA-ri.17 Demographics, medical history, and cerebral MRI were recorded at admission.
 For the control group, inclusion criteria were: age > 55 years; recent MRI with normal diffusion
 sequences (transient ischemic stroke, functional neurological symptoms, or symptoms of peripheral
 origin); exclusion criteria were: cognitive decline (short Informant Questionnaire on Cognitive
 Decline in the Elderly (IQCODE-R) > 3.4); MRI-proven lobar ICH, recent ischemic stroke, or
 Fazekas grading â‰¥ 2 for white matter hyperintensities.
 All eligible patients who gave their consent to participate in the study were included. All serum
 aliquots were kept at -20Â°C until use, with a median storage duration of 19 (3â€“42), 16 (3â€“50), and 27
 (4â€“55) months (range) for the control, CAA-he, and CAA-ri groups, respectively.
 Standard Protocol Approvals, Registrations, and Patient Consents
 The study protocol was approved by the ethics committee â€œParis Ile de France Vâ€. All participants
 representative were provided oral and written information, and gave oral or written consent to
 participate.
 Imaging assessment
                                                                                                                                           5

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Diagnoses were adjudicated by one board-certified neurologist (JC) specialized in stroke, blind to
 biological information. Cerebral lobar microhemorrhages were defined as small round foci of hypo-
 intense signal in T2*-GRE-weighted images, 10 mm or less in brain parenchyma and rated according
 to the microhemorrhages anatomical rating scale.18 Cortical superficial siderosis (cSS) was assessed
 according to the cSS multifocality scale.19
 AÎ² preparations
 Synthetic (>95%) AÎ²1â€“40 and AÎ²1â€“42 peptides (Proteogenix, Schiltigheim, France) were dissolved in
 hexafluoroisopropanol, and 450 Âµg aliquots were evaporated in low retention tubes and stored at -20
 Â°C until use. Before use, lyophilized AÎ² was dissolved in 10ÂµL dimethylsulfoxide (DMSO),
 sonicated for 3 min at 300 Watts. For soluble preparations, aliquots were then mixed with 90 ÂµL
 30mM HEPES 10eq Cu2+ pH 7.4 buffer with 10mM or 160mM NaCl for AÎ²1-42 and AÎ²1-40,
 respectively. For fibril preparations, aliquots were then mixed with 90 ÂµL 0.01N HCl or AÎ²1-40
 coating buffer, incubated at 37Â°C during 72h or 15 days, for AÎ²1-42 and AÎ²1-40, respectively.
 Multiplex ELISA for anti-AÎ² antibody analyses
 Freshly prepared soluble or fibrillar AÎ²1-40 and AÎ²1-42 (hereafter termed s-AÎ²40, s-AÎ²42, f-AÎ²40 or f-
 AÎ²42) were diluted to 15 Âµg/mL in coating buffer (30mM HEPES 160mM or 10mM NaCl (for AÎ²1â€“40
 and AÎ²1â€“42, respectively) 10eq Cu2+ (for monomers) pH 7.4), distributed at 100 ÂµL per well into
 ELISA plates (Greiner BioOne) and incubated 16 hours at 4Â°C. Serial dilutions of serum samples at
 1:50 to 1:12800 in 0.1M Glycine-HCl buffer pH 3.0, were left 40 minutes at 20Â°C for dissociation of
 immune complexes, neutralized to pH 7.4 by adding the same volume of 2xPBS 4% BSA 0.02N
 NaOH, then 100ÂµL were immediately deposited into s-AÎ²40, s-AÎ²42, f-AÎ²40 or f-AÎ²42-coated ELISA
 plates and incubated 1h at 20Â°C. After eight washes with PBS 0.05% Tween-20, bound antibodies of
 each IgG subclass were detected by 16h incubation at 4Â°C of monoclonal anti-human IgG1, IgG2,
                                                                                                                                           6

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 IgG3, or IgG4 antibodies (clones NL16, GOM2, ZG4 and RJ4, respectively). After eight washes with
 PBS 0.05% Tween-20, antibodies belonging to IgG, IgA and IgM classes and IgG subclasses were
 revealed after 1h incubation at 20Â°C with peroxidase-conjugated antisera (anti-mouse IgG for IgG
 subclasses, or anti-human IgG, IgA, and IgM, 1:5000 in washing buffer, Jackson ImmunoResearch
 Inc.). Washed plates were revealed with H2O2/o-phenylene-diamine substrate in 0.15 M urea buffer
 pH 5.0, the reaction stopped with 2N H2SO4, and optical densities (OD) measured at 492 nm. Non-
 specific signals obtained in uncoated wells were subtracted from overall signals retain OD relating to
 specific anti-AÎ² binding. Of note, IgG2 antibodies yielded low binding to AÎ² and unusable dilution
 curves as previously found in 33 AD and controls.12
 Quality management of multiplex ELISA
 Samples were randomized and analyzed blindly to minimize bias due to manipulator and inter-assay
 variability. Randomization was stratified in order to include samples from all clinical groups, so any
 experimental bias would affect all groups comparably. Pools of human sera were used as internal
 standard for inter-experiment normalization, and internal control to assess inter-assay variability.
 Results over 2.5 standard deviation (sd) for one curve parameter were considered invalid.
 Determination of dilution curve parameters
 Serum serial dilution curves follow a sigmoid-shaped signal in semi-logarithmic units, as illustrated
 on Fig 1A.20 The best fitting sigmoid curve parameters were determined by non-linear least square
 approach, following the equation:
                                                         
                                                                                  .  .
 The values of a, b, and c directly relate to sigmoid curve parameters, hence to antibody properties.
 Maximum (a) signal obtained in antibody excess relate to the number of antigen binding sites, hence
                                                                                                                                           7

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 on the diversity of epitope recognition by polyclonal anti-AÎ² antibodies. Titer (ln(b)/c) reflects the x-
 axis position of the curve, and depends on both concentration and avidity of the antibodies. The
 Steepness or Slope of the curve at the inflexion point (â€“c/4a) can vary with cooperativity phenomena
 occurring between distinct antibody binding sites. The apparent Avidity constant was calculated
 through a linearization procedure of the sigmoid curve (Fig 1B).21 In order to ensure appropriate
 goodness-of-fit of experimental data, only curves with R > 0.9 were taken into account.
 Statistical analysis
 For each individual, 96 serological variables were analyzed (Maximum, Titer, Steepness and Avidity
 for anti-soluble and fibrillar AÎ²40 and AÎ²42 IgG, IgA, IgM, IgG1, IgG3, and IgG4). In order to limit
 multiple comparison bias, we chose not to perform univariate analysis. Multiple logistic regression
 models were computed using stepwise variable selection. The criteria for retaining a variable into the
 model were that all variables were significantly associated with the risk of belonging to the diseased
 group (tested by the Waldâ€™s test; p<0.05) and that introducing this variable allowed a significant
 improvement of the model against the (k-1) model, as measured by a significant drop of the residual
 variance (tested by a Likelihood Ratio test; p-value < 0.05). Variance Inflation Factors (VIFs) were
 computed for each final model to ensure the absence of collinearity between variables. A VIF value
 of 1 is obtained when there is no collinearity between variables, while a VIF value > 5 witnesses high
 multicollinearity in the model. Wilcoxonâ€™s test was used to compare the predicted response of the
 models between clinical groups. All statistical analyses were done with R version 3.6.1. The MASS
 package was used for model selection, and the beeswarm package for plots.
 Data Availability Statement
 Data are available upon reasonable request.
                                                                                                                                           8

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Results
 Patient demographics and clinico-radiological data
 The study enrolled 105 participants: 41 healthy aged controls, 46 CAA-he patients, and 18 CAA-ri
 patients. Of note, eight patients from the CAA-he group had cSS but no ICH ; their symptoms were :
 isolated cognitive decline in 3, transient focal episodes in 4 (2 with acute subarachnoidal
 hemorrhage); asymptomatic in one. Median (range) ages were 72 (55â€“89), 79 (59â€“90), 75 (64â€“87)
 years old in the control, CAA-he and CAA-ri groups, respectively. Male/Female ratios were 22/18,
 24/21, and 8/9 in the control, CAA-he and CAA-ri groups, respectively. The main clinical and
 imaging findings in CAA-he and CAA-ri patients are presented in Table I.
 Quality assessment of the multiplex ELISA
 The sigmoid modeling of experimental dilution curves showed excellent overall goodness-of-fit
 (mean RÂ² = 0.97; range stratified by antigen isoform: [0.97â€“0.98]; range stratified by antibody
 isotype: [0.95â€“0.99]). This confirmed that experimental dilution curves are appropriately described
 by the sigmoid model. Internal control mean coefficients of variation (CV) were inferior to 20% for
 all four parameters of all antibody isotypes and all AÎ² isoforms (mean CV: 16%, 7%, 16%, and 12%,
 for maxima, titer, steepness, and avidity, respectively). This validated the multiplex ELISA as a
 reliable and reproducible method for assessing anti-AÎ² antibody features.
 Serum anti-AÎ² antibody patterns associated with CAA
 Table II presents the anti-AÎ² serologic parameters associated with CAA against controls. These
 parameters are those included in the multivariable logistic regression model after stepwise variable
 selection. Fig 2A presents the predicted response resulting from this CAA-model applied to each
 individual. This predicted response is associated with the probability of presenting CAA or not, and
                                                                                                                                           9

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 is modeled using the individual anti-AÎ² profile regarding parameters presented in Table 2. In this
 complex profile, a higher diversity and concentration of anti-s-AÎ²40 IgG3, a higher avidity of anti-s-
 AÎ²40 IgG4 and a higher steepness of anti-f-AÎ²42 IgG4 were associated with an increased probability
 of belonging to the CAA group. A lower diversity of anti-s-AÎ²40 IgM, a lower avidity of anti-s-AÎ²42
 IgA, and a lower concentration of anti-f-AÎ²42 IgG1 were also associated with an increased
 probability of belonging to the CAA group. All these variables, contributed independently to the
 model, without multicollinearity (all Variance Inflation Factors (VIFs) < 1.8).
 The serological anti-AÎ² antibody profile associated with CAA-he as compared to healthy aged
 controls (Table 2 and Fig 2B) also included lower diversity of anti-s-AÎ²40 IgM and lower avidity of
 anti-s-AÎ²42 IgA. Regarding the IgG4 isotype, CAA-he patients displayed higher concentrations of
 anti-s-AÎ²40 IgG4, and lower concentrations and avidity of anti-AÎ²42 IgG4, respectively. CAA-he
 patients also displayed lower avidity of anti-f-AÎ²42 IgG1 as compared with healthy aged controls. Of
 note, excluding the 8 CAA-he patients that presented cSS without ICH did not change variables
 present in this model. All these variables and independently contributed to the model, without
 multicollinearity (all VIFs < 1.3).
 As found in the CAA model, CAA-ri patients (Table 2 and Fig 2C) displayed lower diversity of anti-
 s-AÎ²40 IgM, as also found for CAA-he patients, but also a higher diversity of anti- s-AÎ²40 IgG3, and a
 higher steepness of anti-fibrillar AÎ²42 IgG4 dilution curve. Conversely, CAA-ri patients displayed a
 lower steepness of anti- s-AÎ²42 IgG4 and anti-s-AÎ²40 IgA. All these variables contributed
 independently to the model, without multicollinearity (all VIFs < 1.4).
 Discussion
 Analyses of blood anti-AÎ² antibodies demonstrate complex serological profiles in CAA, displaying
 distinctive features in CAA-he and CAA-ri patients. This proof-of-concept study suggests: i)
                                                                                                                                        10

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 evidence of a link between anti-AÎ² antibody responses and CAA; ii) existence of defined circulating
 anti-AÎ² antibody species associated with distinct pathological phenotypes. In brief, clinical
 manifestations of CAA appear to relate, at least in part, to a biased natural antibody repertoire or
 abnormal responses to pathological AÎ² peptide. However, at this stage, these serological profiles may
 not be used as biomarkers.
 The causal relevance of these observations remains to be elucidated. Different naturally occurring
 anti-AÎ² repertoires could be susceptibility factors for developing CAA, possibly by interfering with
 the clearance of cerebral AÎ². Cerebrovascular AÎ² deposits may also induce anti-AÎ² auto-immune
 responses emerging from the natural antibody repertoire. Finally, such induced anti-AÎ² antibody
 species might enhance CAA and/or trigger hemorrhagic or inflammatory manifestations, as
 suggested in experimental mouse models.7,8
 Although this multivariable modeling approach does not allow pathophysiological conclusions about
 the role of given anti-AÎ² species in CAA, it suggests hypotheses and drives attention towards
 potentially relevant anti-AÎ² features. With the notable exception of anti-fibrillar AÎ²1-42 IgG4, all
 serologic parameters relating to AÎ²1-42 were lower in CAA. Regarding antibodies reacting with AÎ²1-
 40, our results show preferential developments of IgG3 and IgG4 antibody responses. Interestingly,
 lower diversity of anti-soluble AÎ²1-40 IgM was the only common feature of CAA-he and CAA-ri
 patients. This could indicate an IgM response preferentially directed toward some particular
 pathogenic AÎ²1-40 epitopes in response to AÎ²1-40 cerebrovascular deposits.
 The role of antibody isotypes in anti-AÎ² antibodies related CAA manifestations is elusive. In AD
 patients treated with monoclonal anti-AÎ² antibodies, amyloid related imaging abnormalities with
 vasogenic edema (ARIA-E) or with hemorrhagic features (ARIA-H) were initially reported with
 antibodies of IgG1 subclass.22-24 No ARIA-E but ARIA-H were yet reported in patients receiving
                                                                                                                                        11

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 anti-AÎ² IgG4 (Crenezumab),25 while the existence of both remains uncertain for IgG2
 (Ponezumab)26,27 None of the monoclonal anti-AÎ² antibodies used in AD immunotherapy trials was
 of the IgG3 subclass. Like IgG1, IgG3 antibodies display potent effector functions including
 complement classical pathway activation and phagocytic and cytotoxic cell activation. IgG3 were
 thought to be more pathogenic than other IgG subclasses in anti-neutrophil cytoplasm antibody
 (ANCA)-associated vasculitis.28
 Lobar ICH, MH and cSS were also reported in active immunotherapy trial CAD106, designed for
 eliciting AÎ²-specific antibodies without T-cell response. Lobar ICH occurred in a patient without
 anti-AÎ² IgG response to CAD106, but his anti-AÎ² IgM status was not reported.29 It is worth noting
 that in ANCA-associated vasculitis, the presence of transient but recurrent IgM-ANCA is associated
 with a higher severity mainly due to acute hemorrhagic pulmonary manifestations.30
 The main risks factors for CAA are age, coincidental Alzheimerâ€™s disease, and ApoE genotypes, with
 controversy regarding the respective roles of Îµ2 and Îµ4 alleles.31 We accounted for age and cognitive
 decline by selecting aged healthy controls without cognitive decline, and CAA patients with normal
 MMSE. One potential limitation is that, due to unavailable material, ApoE genotypes could not be
 evaluated in this study. However, used diagnostic criteria for CAA-he and CAA-ri are independent of
 the ApoE genotype. Part of the serologic diversity might relate to ApoE genotypes, since both Îµ232,33
 and Îµ434 alleles have been linked to more severe CAA, with vasculopathies and hemorrhagic
 phenotypes. This question should be addressed in further studies.
 In previous studies, serum anti-AÎ² antibodies were mostly analyzed in the context of Alzheimerâ€™s
 disease, with various results reported by different authors using distinct methods.12-14
 Neuropathological CAA is virtually present in all patients with AD pathology.35 However, lobar
 microbleeds evoking CAA are present in only about 20% AD patients36 while lobar ICH and
                                                                                                                                        12

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 spontaneous manifestations similar to CAA-ri are rare in AD. This may be explained by the distinct
 CAA neuropathological phenotypes in AD and in patients with CAA clinical manifestations.37
 Whether AD patients with and without cerebral microbleed would present with different anti-AÎ²
 serological signatures as compared to CAA-he and CAA-ri patients is thus likely and will be
 addressed in further studies.
 Anti-AÎ² antibodies circulate mostly as immune complexes,11 but whether these complexes include
 circulating AÎ², cross-reactive proteins, and/or anti-idiotype antibodies is not known. As previously
 performed by others,11-12,38 we used acidic dissociation of serum samples followed by
 extemporaneous neutralization to analyze all circulating anti-AÎ² antibodies regardless of their free or
 bound state. We used high purity synthetic AÎ² preparations and appropriate blank controls to ensure
 binding specificity. Of note, given the low specific signal obtained with non-dissociated samples
 once the background is subtracted, dilution curve analysis could not have been performed on non-
 dissociated samples. That anti-AÎ² antibodies circulate mostly as immune complexes also raises
 questions regarding plasma AÎ² levels measurements. Contradictory results exist on circulating AÎ²
 levels in CAA.39,40 The circulating levels of free AÎ² should depend on the concentrations and
 affinities of circulating anti-AÎ² antibodies, and it is possible that the experimental conditions in
 which AÎ² measurements are performed cannot fully circumvent AÎ² masking by circulating anti-AÎ²
 antibodies.
 In conclusion, this correlative proof-of-concept study demonstrates distinct serum anti-AÎ² antibody
 patterns in CAA and its hemorrhagic and inflammatory manifestations. Larger prospective and
 experimental studies could elucidate the triggering role of anti-AÎ² antibodies in spontaneous or
 immunotherapy-induced CAA manifestations, and provide appropriate biomarkers.
                                                                                                                                        13

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Acknowledgments
 We thank Dr Margaret Goodall (Birmigham, UK) for providing anti-IgG subclass antibodies.
 Author contributions
 Study concept and design: YC, JC, SA, PA. Data acquisition and analysis: YC, JC, DD, JF, MF, FK,
 TC, TA, XA, ZB, TdB, CC, GT, RP, AW, MS, DR, CC. Drafting the manuscript and figures: YC,
 JC, GD, CC, SA, PA.
 Conflict of interest
 The authors declare that the research was conducted in the absence of any commercial or financial
 relationships that could be construed as a potential conflict of interest.
                                                                                                                                        14

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 References
 1. Charidimou A, Boulouis G, Gurol ME, Ayata C, Bacskai BJ, Frosch MP, et al. Emerging concepts
 in sporadic cerebral amyloid angiopathy. Brain 2017a; 140: 1829â€“50.
 2. BÃ©jot Y, Cordonnier C, Durier J, Aboa-EboulÃ© C, Rouaud O, Giroud M. Intracerebral
 haemorrhage profiles are changing: results from the Dijon population-based study. Brain 2013; 136:
 658â€“64.
 3. Salvarani C, Hunder GG, Morris JM, Brown RD Jr, Christianson T, Giannini C. AÎ²-related
 angiitis: comparison with CAA without inflammation and primary CNS vasculitis. Neurology 2013;
 81: 1596â€“603.
 4. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT et al. Amyloid-related
 imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the
 Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7:367â€“85.
 5. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, et al. Anti-amyloid
 Î² autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-
 modifying therapies. Ann Neurol 2013; 73: 449â€“58.
 6. DiFrancesco JC, Longoni M, Piazza F. Anti-AÎ² Autoantibodies in Amyloid Related Imaging
 Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and
 Cerebral Amyloid Angiopathy. Front Neurol 2015; 6: 207.
 7. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M et al. Cerebral
 hemorrhage after passive anti-Abeta immunotherapy. Science. 2002; 298: 1379.
 8. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, et al.
 Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated
 micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci USA 2009; 106: 4501â€“06.
 9. Krestova M, Hromadkova L, Ricny J. Purification of Natural Antibodies Against Tau Protein by
 Affinity Chromatography. Methods Mol Biol 2017; 1643: 33-44.
 10. Folke J, Rydbirk R, LÃ¸kkegaard A, et al. Distinct Autoimmune Anti-Î±-Synuclein Antibody
 Patterns in Multiple System Atrophy and Parkinson's Disease. Front Immunol 2019; 10: 2253.
 11. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K et al.
 Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal
 aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA. 2009; 106: 12145â€“50.
 12. DorothÃ©e G, Bottlaender M, Moukari E, de Souza LC, Maroy R, Corlier F et al. Distinct patterns
 of antiamyloid-Î² antibodies in typical and atypical Alzheimer disease. Arch Neurol 2012; 69: 1181â€“
 5.
 13. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B et al. Reduced levels of amyloid beta-
 peptide antibody in Alzheimer disease. Neurology 2001; 57: 801â€“5.
                                                                                                                                        15

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 14. Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T et al. Increased levels of antigen-
 bound Î²-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.
 PLoS One 2013; 8:e68996.
 15. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid
 angiopathy: validation of the Boston criteria. Neurology 2001; 56: 537â€“9.
 16. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M et al. Prevalence of superficial
 siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74: 1346â€“50.
 17. Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, et al. Validation of
 Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related
 Inflammation. JAMA Neurol 2016; 73: 197â€“202.
 18. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, JÃ¤ger HR et al. The Microbleed
 Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 2009;
 73: 1759â€“66.
 19. Charidimou A, Boulouis G, Roongpiboonsopit D, Auriel E, Pasi M, Haley K et al. Cortical
 superficial siderosis multifocality in cerebral amyloid angiopathy: A prospective study. Neurology
 2017b; 89: 2128â€“35.
 20. Cheung YB, Xu Y, Remarque EJ, Milligan P. Statistical estimation of antibody concentration
 using multiple dilutions. J Immunol Methods 2015; 417: 115â€“23.
 21. Orosz F, OvÃ¡di J. A simple method for the determination of dissociation constants by
 displacement ELISA. J Immunol Methods 2002; 270: 155â€“62.
 22. Ostrowitzki S, Deptula D, Thurfjell L, Scheltens P, Barkhof F, Nikolcheva T et al. Mechanism of
 amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;
 69: 198â€“207.
 23. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al. Two phase 3 trials of
 bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322â€“33.
 24. Sevigny J, Chiao P, BussiÃ¨re T, Weinreb PH, Williams L, Maier M et al. The antibody
 aducanumab reduces AÎ² plaques in Alzheimer's disease. Nature 2016; 537: 50â€“6.
 25. Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W et al. ABBY: A phase 2
 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 2018; 90:e1889-
 97.
 26. Leurent C, Goodman JA, Zhang Y, He P, Polimeni JR, Gurol ME, et al. Immunotherapy with
 ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol 2019; 6: 795-806.
 27. Chantran Y, Capron J, Alamowitch S, Aucouturier P. AntiAÎ² antibodies and cerebral amyloid
 angiopathy complications. Front Immunol 2019; 10: 1534.
 28. Mulder AH, Stegeman CA, Kallenberg CG. Activation of granulocytes by anti-neutrophil
 cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3
 subclass of ANCA. Clin Exp Immunol 1995; 101: 227â€“32.
                                                                                                                                        16

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 29. Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, et al. Long-term treatment
 with active AÎ² immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther
 2015; 7: 23.
 30. Clain JM, Hummel AM, Stone JH, Fervenza FC, Hoffmann GS, Kallenberg CGM, et al.
 Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and
 microscopic polyangiitis. Clin Exp Immunol 2017; 188: 174â€“81.
 31. Charidimou A, Martinez-Ramirez S, Shoamanesh A, Oliveira-Filho J, Frosch M, Vashkevich A,
 et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease
 phenotypes. Neurology 2015; 84: 1206-12.
 32. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of
 apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol
 1997; 41: 716-21.
 33. Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy AE, Liao A, et al. Association of
 apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998; 50:
 961-5.
 34. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid
 angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol 1998; 57:
 353-9.
 35. Jellinger KA, Lauda F, Attems J. Sporadic cerebral amyloid angiopathy is not a frequent cause of
 spontaneous brain hemorrhage. Eur J Neurol 2007; 14: 923-8.
 36. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and
 severity of microbleeds in a memory clinic setting. Neurology 2006; 66: 1356-60.
 37. Thal DR, Ghebremedhin E, RÃ¼b U, Yamaguchi H, Del Tredici K, Braak H. Two types of
 sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002; 61: 282-93.
 38. Li Q, Gordon M, Cao C, Ugen KE, Morgan D. Improvement of a low pH antigen-antibody
 dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci
 2007; 8: 22.
 39. Greenberg SM, Cho HS, O'Donnell HC, Rosand J, Segal AZ, Younkin LH, et al. Plasma beta-
 amyloid peptide, transforming growth factor-beta 1, and risk for cerebral amyloid angiopathy. Ann N
 Y Acad Sci. 2000; 903: 144-9.
 40. Hernandez-Guillamon M, Delgado P, Penalba A, Rodriguez-Luna D, Molina CA, Rovira A, et al.
 Plasma Î²-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke.
 Neurodegener Dis 2012; 10: 320-3.
                                                                                                                                        17

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Figure legends
 Figure 1. Determination of dilution curve parameters by sigmoid modeling and linearization
 procedure. A. Dilution curve obtained from a human serum sample following acidic dissociation of
 circulating immune complexes and neutralization, incubated on coated soluble AÎ²1-42 and revealed
 with anti-IgG secondary antibody. The dashed thick line represents the sigmoid modeling of the
 curve, accurately described by i) the y-axis value of the left-sided plateau (Maximum); ii) the x-axis
 value at the inflexion point (Titer); iii) the slope at the inflexion point (Steepness). B. Linearization of
 the same experimental points and sigmoid model, which allows the determination of the apparent
 constant of avidity.
 Figure 2. Serological differences associated with CAA clinical phenotypes. A, CAA-model
 predicted value using the logistic multivariable regression model presented in Table 2, upper part. B,
 CAA-he model predicted values using the logistic multivariable regression model presented in Table
 2, middle part. C, CAA-ri model predicted values using the logistic multivariable regression model
 presented in Table 2, lower part. *:p<0.05; **: p<0.01; ***: p<0.001. Wilcoxonâ€™s test.
                                                                                                                                        18

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Table I. Clinical and radiological characteristics of patients with cerebral amyloid angiopathy
 CAA-ri patients (n=18)
   Onset < 1 month                                                                                   8
   Symptoms
     Cognitive decline                                                                               17
     Neurologic deficit                                                                              11
     Epilepsy                                                                                        6
     Headache                                                                                        5
   Histological diagnosis                                                                            2
   MRI findings
     Asymetric white matter hypersignal reaching U fibers                                            17
     Meningeal gadolinium enhancement (n=14 injected MRIs)                                           6
   Treatment
     Steroid alone                                                                                   11
     Steroid + Cyclophosphamid                                                                       6
     Nonea                                                                                           3
   Outcome (n=17)b
     Clinical and radiological improvement                                                           13
     Radiological improvement alone                                                                  3
 CAA-he patients (n=46)
   MRI findings
     lobar micro-hemorrhages                                                                         45
     cSS score (0-1-2-3-4)                                                                           13/15/6/7/5
     Fazekas score (1-2-3)                                                                           9/21/16
                                                                                                                                        19

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
  Modified Boston criteria for CAA (definite/probable)                                               3/43
 Abbreviations: CAA, cerebral amyloid angiopathy. CAA-he, cerebral amyloid angiopathy related
 intracerebral hemorrhage. CAA-ri, cerebral amyloid angiopathy-related inflammation. ICH,
 intracerebral hemorrhage. cSS, cortical superficial siderosis. aall with clinical and radiological
 improvement. bone patient was lost during follow-up
                                                                                                                                        20

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
   (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
 Table II. Multivariable logistic regression models for CAA, CAA-he, and CAA-ri against
 healthy aged controls
 CAA model
                                                                     Standard                                  Residual
 Variables                                         Estimates         errors          Z-val.     P-val.         deviances           P-val.
                                                   0.13              6.57                                      140.5
 a
   Anti-s-AÎ²40 IgG3 Maximum                        2.89              0.92            3.14       0.0017         134.0               0.011
  Anti-s-AÎ²40 IgG3 Titer                           4.03              1.16            3.48       0.0005         123.6               0.0013
  Anti-s-AÎ²40 IgG4 Avidity                         2.29              0.94            2.44       0.015          117.6               0.014
 a
   Anti-f-AÎ²42 IgG4 Steepness                      3.74              1.32            2.84       0.0045         111.5               0.013
 b
   Anti-s-AÎ²40 IgM Maximum                         -3.10             1.02            -3.05      0.0023         102.5               0.0027
 c
   Anti-s-AÎ²42 IgA Avidity                         -3.48             1.13            -3.07      0.0021         92.9                0.0019
  Anti-f-AÎ²42 IgG1 Titer                           -3.81             1.58            -2.42      0.016          86.5                0.012
 CAA-he model
                                                                     Standard                                  Residual
 Variables                                         Estimates         errors          Z-val.     P-val.         deviances           P-val.
                                                   42.14             11.84                                     120.32
  Anti-s-AÎ²40 IgG4 Titer                           3.30              1.11            2.97       0.0030         111.57              0.0031
  Anti-f-AÎ²42 IgG4 Titer                           -6.41             1.95            -3.29      0.0010         98.41               0.0003
  Anti-f-AÎ²42 IgG1 Avidity                         -4.65             2.04            -2.28      0.023          90.72               0.0056
 c
   Anti-s-AÎ²42 IgA Avidity                         -2.77             1.06            -2.61      0.0092         85.59               0.024
 b
   Anti-s-AÎ²40 IgM Maximum                         -2.09             1.01            -2.06      0.039          80.95               0.031
  Anti-s-AÎ²42 IgG4 Avidity                         -2.87             1.24            -2.32      0.020          74.92               0.014
 CAA-ri model
                                                                                                                                        21

medRxiv preprint doi: https://doi.org/10.1101/2020.10.07.20208330.this version posted October 9, 2020. The copyright holder for this preprint
    (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           All rights reserved. No reuse allowed without permission.
                                                                     Standard                                   Residual
 Variables                                         Estimates         errors          Z-val.     P-val.          deviances           P-val.
                                                   10.75             5.78                                       72.58
 a
   Anti-s-AÎ²40 IgG3 Maximum                        4.15              1.55            2.68       0.007           63.92               0.0032
 a
   Anti-f-AÎ²42 IgG4 Steepness                      4.01              1.70            2.36       0.018          58.38                0.019
  Anti-s-AÎ²40 IgA Steepness                        -18.53            8.23            -2.25      0.024           54.08               0.038
  Anti-s-AÎ²42 IgG4 Steepness                       -12.19            5.25            -2.32      0.020           46.96               0.0076
 b
   Anti-s-AÎ²40 IgM Maximum                         -2.40             1.21            -1.99      0.047           40.68               0.012
 a
   : Variables shared between the CAA and the CAA-ri models. b: Variables shared between the CAA,
 the CAA-he and the CAA-ri models; c: Variables shared between the CAA and the CAA-he models;
                                                                                                                                         22


